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Background: Lichen Planus, LP, is an inflammatory disease of possible autoimmune origin affecting mainly oral 
and genital mucosa and skin. According to the WHO oral LP is considered a potentially malignant disorders. The 
p16 tumour suppressor protein can act as an inhibitor of cyclin dependent kinases 4 and 6 and thus down regulate 
cell cycle progression. Since the discovery of p16 several studies have evaluated its expression in various forms 
of human cancers. The aim of this study was to evaluate and compare the expression of p16 in oral and genital LP 
and corresponding healthy mucosa.
Material and Methods: A total of 76 cases of oral LP (OLP), 34 cases of genital LP (GLP), 12 cases of healthy oral 
and 9 cases of healthy genital mucosa were analysed by the use of immunohistochemistry. 
Results: Data showed p16 to be highly expressed in both oral and genital LP, higher than in oral (p=0.000), and 
genital controls (p=0.002). 
Conclusions: Results suggest that the over-expression of p16 seen in LP play a part in the histopathology of the 
disease.




Lichen planus (LP) is a chronic inflammatory disease 
affecting skin and mucosa. The origin of the disease is 
unknown but autoimmunity has been suggested to play 
a part in the pathobiology (1-3). The disease is thought 
to be mediated by cytotoxic T-cells acting against the 
oral epithelium (4). A recent study showed that more 
than 50% of oral LP (OLP) patients also suffer from 
genital LP (GLP) and that approximately 1/3 of OLP pa-
tients also have skin lesions (5). GLP lesions are usually 
symptomatic with various degrees of pain and burning 
sensations. In contrast to OLP, which is classified as a 
potentially malignant disorder by WHO (6) there is little 
evidence for malignant transformation of GLP. The ma-
lignant potential of OLP has, however, been extensively 
debated. In a review article from 1999, van der Meij 
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concluded that the rate of malignant transformation for 
OLP should be considered lower than 0.2%, and that 
more clear and universally accepted diagnostic criteria 
are needed (7). However, in several studies, a maligni-
fication rate of 0.5-2% is reported (8). Such a rate is, 
however, considered doubtful as it would make OLP the 
cause of oral cancer in different parts of the world (7). 
The p16 protein is the product of the CDKN2 gene lo-
cated on chromosome 9p21. It plays a crucial role in reg-
ulation of the cell cycle (9). p16 prevents the association 
of CDK4/CDK6 with cyclin D which in turn prevents 
phosphorylation of important substrates essential for 
transit through the G1 phase of the cell cycle, resulting 
in inhibition of cell proliferation (9). Over-expression of 
p16 has been seen in 13% to 50% of oral squamous cell 
carcinoma (4,10).
There are so far only a few studies on the expression 
of p16 in OLP, and results vary with expression rates 
between 27% up to almost 75% depending on quantifi-
cation techniques and choice of cut off (4,11-13). Some 
of these studies have suggested a positive role for p16 in 
detection of oral dysplasia and also a role in progression 
to oral squamous cell carcinoma (13,14), whereas other 
studies claim that p16 cannot be used as a reliable pa-
rameter for identification of malignant transformation 
of OLP (12,15). In contrast to OLP, which is classified, 
as a premalignant condition there is little evidence of 
malignant transformation of erosive GLP. There is also 
an ongoing discussion whether OLP and GLP are the 
same disease appearing in different mucosal sites.To 
shed light on this issue we here included OLP and GLP 
as well as corresponding normal tissue in a study of the 
expression of the cell cycle regulator p16. The aim of 
this study was to evaluate and compare the expression 





Biopsies from 79 patients diagnosed with OLP and 24 
patients with genital LP were retrieved from the archive 
at Clinical Pathology, Umeå University. The diagnosis 
of OLP and GLP was both clinically and histologically 
verified. All cases were in an active state, histologically 
showing a well-defined inflammatory infiltrate. The 
OLP group consisted of 53 females (67%) and 26 males 
(33%) and of the GLP patients 18 were females (75%) 
and 6 males (25%). The OLP group had an age range of 
21-89 years with a mean age of 57 and the GLP group 
an age range of 33-84 years with a mean age of 51 years 
(Table 1). Of  79 OLP samples 57 were collected from 
buccal  mucosa, 11 from gingiva, 3 from tongue, 2 from 
palate  and remaining 6 from other sites. 
Fifteen biopsies from normal healthy oral mucosa and 
nine biopsies from normal healthy genital mucosa were 
also collected and used as control group. All together 
a total of 127 biopsies were included in the study (Ta-
ble 1). The study was approved by the Ethical Review 
Board at Umeå University (dnr 2013-252-32M). 
-Immunohistochemistry
Five µm sections were cut from formalin fixed paraffin 
embedded samples. Sections were dewaxed, rehydrated 
by standard procedures and subjected to boiling in 10 
mM citrate buffer, pH 6.0 for 15 min using a microwave 
oven for antigen retrieval. 
The antibody used for p16 (Santa Cruz Biotechnology 
inc, Europe) was diluted 1:200. Staining was performed 
in a Ventana Bench Mark Ultra staining machine (Ven-
tana Medical Systems, Inc, Tucson, AZ, USA) accord-
ing to the manufacturer’s recommendations. 
-Scoring
Samples were scored regarding percentage of epithelial 
cells expressing p16 and intensity of staining. Propor-
tion of p16 expressing cells was divided into six stages 
where 1=0–4%, 2=5–19%, 3=20–39%, 4=40–59%, 
5=60–79% and 6=80–100%, and intensity in four 
stages where 0=negative, 1=weak, 2=intermediate and 
3=strong staining. By multiplying percentage of p16 
expressing cells with intensity for each sample a quick 
score (QS) ranging from 0 to 18 was obtained (16). The 
p16-stained slides were evaluated independently by four 
of the authors (KD, JO, RZ and ME). Depending on the 
result, the material is divided in to 3 groups. Those who 
did not express p16 (QS = 0), those with moderate ex-
pressions (QS 1-5) and those with high expressions (QS 
6-18).
In cases of disagreement slides were discussed in a joint 
session until consensuses was reached. 
-Statistical analysis
Statistical analysis was performed using IBM SPSS sta-
tistics v22. The non-parametric method Mann-Whitney 
was used. Significance level was set at p=0.05
Oral LP
Male        Female
Genital LP
Male        Female
Oral Control
Male       Female
Genital Control
Male    Female
Number 26 53 6 18 9 6 0 9
Range year 21-73 24-89 33-54 39-84 25-59 27-56 42-78
Mean age 53.5 60 44.1 57.1 46.8 43.8 65.5
Table 1: Data on patients and controls (OC = Oral Control and GC= Genital Control) regarding gender and age.
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Results
A total of 103 slides from OLP and GLP lesions as well 
as 24 controls were evaluated. 
Cases with QS> 0 were regarded as positive. Those with 
moderate expressions (QS 1-5) and those with strong 
expressions (QS 6-18).
In the OLP group all but two of the 79 samples were 
positive (97%), and the majority, 78.5%, showed a QS of 
6-18. In the GLP group all cases were positive, and most 
samples, 66.5% had a QS of 6-18. 
Among the oral controls 53% were negative, and none 
of the samples had a QS over 5. The genital controls had 
one negative case only and two cases with QS of 6-18. 
Fig. 1: Representative IHC staining of p16 in OLP at X20 magnification. a) QS= 2, b) QS=6, c) QS= 12 
and  d) QS= 18.
In the group with a” moderate” QS, defined as a QS 
of 1-5, control samples dominated, 47% of the oral and 
67% of the genital controls, compared to 19% and 33.5% 
respectively of the OLP and GLP cases. 
Expression of p16 was significantly higher in OLP 
compared to control oral mucosa (OC) p=0.000, and 
the same pattern was seen in GLP compared with con-
trol genital mucosa (GC) p=0.002 (Fig. 1). The mean 
QS for the OLP group was 8.7 compared to 1.3 for 
controls, and 7.3 for GLP compared to 2.6 for genital 
controls.
Representative stainings are shown in Figure 2, and QS 















Fig. 2: Box plot chart showing distribution of QS for OLP and 
GLP and corresponding control mucosa. (OC = Oral Control 
and GC= Genital Control).
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p16 QS OLP OralControl GLP GenitalControl
0 2       (2.5%) 8           (53%) 0 1           (11%)
1-5 15    (19%) 7           (47%) 8         (33.5%) 6          (67%)
6-18 62    (78.5%) 0 16       (66.5%) 2           (22%)
79    (100%) 15         (100%) 24       (100%) 9         (100%)
Table 2: Results from QS of OLP, GLP and corresponding normal tissues.
Discussion
This is, to our knowledge, the first study evaluating 
expression of p16 in genital LP in comparison to oral 
LP as well as normal corresponding mucosa. Malignant 
transformation of LP is a controversial issue and even if 
there are numerous publications no consensus has been 
reached (17). Even though GLP is not classified as a pre-
malignant condition by WHO there are reports regard-
ing malignant transformation of erosive GLP (18,19)  
Overexpression of p16 has been reported in different 
types of cancer including oral squamous cell carcinoma 
(4,10). Over the past decade different results have been 
published regarding the relationship between expres-
sion of p16 in normal mucosa, oral premalignant lesions 
and oral cancer (4,12,14). 
Data from the present study showing p16 to be signifi-
cantly highly expressed in both OLP and GLP, while 
expression was relatively low in healthy control samples 
is in accordance with some of the previous studies per-
formed on OLP (4,12,13). In contrast, as far as we know, 
no data on p16 expression in genital LP is available.
p16 can by inhibiting the cdk4/cdk6 complex  regulate 
the cell cycle and thus also gene expression, (20). High 
expression of p16 could therefore be an indication of cell 
cycle deregulation. p16 can in certain tumour types like 
tonsillar cancer act as a surrogate marker for high risk 
Human Papilloma Virus (HPV) (21), whereas no such 
correlation is seen in tongue cancer (11). A recent study 
by Montebugnoli et al also showed lack of association 
between p16 expression and HPV in OLP (22). 
In LP lesions increased levels of TNF- α and IFN-γ are 
seen (23), and cytokines like interferons and TNF-α 
have a significant role in initiation of inflammation. A 
combination of IFN-γ and TNF- α further induces p16 
and accordingly permanent growth arrest (4,12). Serum 
levels of TNF-α are known to be higher in OLP patients 
compared to healthy individuals (24), and TNF- α has 
also been seen to be overexpressed in basal keratino-
cytes in patients with OLP (25). The higher p16-expres-
sion seen in our LP-samples could thus be caused by the 
cytokine activity in OLP and GLP causing inflamma-
tory progression and in turn protection from cancer de-
velopment. The role of TNF is, however, controversial, 
where some studies have shown high concentrations of 
TNF- α to act as a tumour suppressor in animal models 
whereas low levels in contrast can induce cancer (26). 
In addition there are some evidence from animal models 
that TNF in high concentration is capable of killing tu-
mour cells (27). IFN-γ another cytokine overexpressed 
in LP has several roles in initiating and maintaining in-
flammation and is involved in events  associated with up 
regulation of p16 (28)
In oral squamous cell carcinoma high p16 expression 
has been correlated to better prognosis (10,29) and low 
expression to increased risk of relapse (30). The in-
creased expression of p16 that we saw could thus ex-
ert a protection against malignant transformation. Data 
published by Natarajan et al presented a role for p16 
in wound healing and senescence. p16 together with 
laminin 5 is involved in a hyper motility/growth arrest 
response when keratinocytes are exposed to a compro-
mised basement membrane. (31) 
In conclusion, we show statistically significantly higher 
expression of p16 in OLP and GLP compared to normal 
oral and genital mucosa and suggest that this over-ex-
pression may act as a protection against malignant trans-
formation. Furthermore, data indicate that lichen planus 
is one general disease establishing in different locations.
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